Drugs / Carbon Nanoparticles
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05229874 | Jan 2022 → Mar 2023 | gastric cancer | Hebei Medical University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04759820 | Jan 2021 → Jun 2022 | — | LI XIN-XIANG | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06791005 | Jan → Jun 2025 overdue | thyroid gland papillary carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 3 | NCT02123407 | Dec 2013 → Jun 2014 | gastric cancer | Peking University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02724176 | Jan 2012 → Jan 2016 | thyroid gland papillary carcinoma | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carbon Nanoparticles | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02123407 ↗ |
| Modality | Diagnostic / imaging agent | “As a novel lymphatic tracer” NCT02724176 ↗ |
| Route | Other | “injected into the subserosa of stomach” NCT02123407 ↗ |